Reports Q4 revenues EUR 4.28B vs. EUR 5.53B last year. "We made significant progress in 2022 by advancing our pipeline and launching the world’s first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine. In addition, multiple new modalities achieved encouraging clinical data and we progressed nine new programs into clinical trials," said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. "As we look to 2023 and beyond, we plan to continue investing in our transformation with a focus on building commercial capabilities in oncology and working towards registrational trials. Our mid-term goal is to seek approval for multiple oncology products in cancer indications with high unmet medical need."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNTX:
- BioNTech Announces New ADS Repurchase Program
- BNTX Down Even as Q4 Earnings Beat Estimates
- BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Biontech Se Sponsored Adr (BNTX) Q4 Earnings Cheat Sheet
- BioNTech price target lowered to $210 from $272 at H.C. Wainwright
